Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Down 12.8% in December

Gossamer Bio, Inc. (NASDAQ:GOSS) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 6,120,000 shares, a decline of 12.8% from the December 15th total of 7,020,000 shares. Based on an average daily volume of 1,330,000 shares, the short-interest ratio is currently 4.6 days.

Institutional Investors Weigh In On Gossamer Bio

Several large investors have recently made changes to their positions in GOSS. Marshall Wace LLP grew its holdings in Gossamer Bio by 170.8% in the 2nd quarter. Marshall Wace LLP now owns 3,335,511 shares of the company’s stock worth $3,002,000 after buying an additional 2,103,766 shares in the last quarter. NEA Management Company LLC boosted its position in Gossamer Bio by 14.2% during the 2nd quarter. NEA Management Company LLC now owns 18,093,034 shares of the company’s stock worth $16,300,000 after acquiring an additional 2,255,025 shares during the period. GSA Capital Partners LLP bought a new position in shares of Gossamer Bio in the third quarter worth $67,000. US Bancorp DE acquired a new position in shares of Gossamer Bio during the third quarter valued at $39,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Gossamer Bio by 67.4% during the second quarter. The Manufacturers Life Insurance Company now owns 310,213 shares of the company’s stock valued at $279,000 after purchasing an additional 124,913 shares in the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a report on Monday, November 11th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $9.20.

Gossamer Bio Stock Performance

Shares of NASDAQ GOSS traded down $0.04 during mid-day trading on Friday, hitting $0.96. The company had a trading volume of 817,985 shares, compared to its average volume of 1,082,774. Gossamer Bio has a 12 month low of $0.50 and a 12 month high of $1.60. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The firm’s 50 day simple moving average is $0.84 and its two-hundred day simple moving average is $0.91.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. The firm had revenue of $9.48 million for the quarter, compared to the consensus estimate of $4.52 million. As a group, research analysts anticipate that Gossamer Bio will post -0.28 earnings per share for the current fiscal year.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.